Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial

Annick Vanclooster; Cees van Deursen; Reggy Jaspers; David Cassiman; Ger Koek

doi:10.1053/j.gastro.2017.06.006

Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial

Annick Vanclooster, Cees van Deursen, Reggy Jaspers, David Cassiman, Ger Koek^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performedwhen serum ferritin was >100 mu g/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy.

Original language	English
Pages (from-to)	678-680.e2
Number of pages	5
Journal	Gastroenterology
Volume	153
Issue number	3
DOIs	https://doi.org/10.1053/j.gastro.2017.06.006
Publication status	Published - Sept 2017

Keywords

Hereditary Hemochromatosis
Proton Pump Inhibitors
Randomized Clinical Trial
HEREDITARY HEMOCHROMATOSIS
IRON

Access to Document

10.1053/j.gastro.2017.06.006

Cite this

@article{b0f1d9a787fb4abe810de28c0e490267,

title = "Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial",

abstract = "Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performedwhen serum ferritin was >100 mu g/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy.",

keywords = "Hereditary Hemochromatosis, Proton Pump Inhibitors, Randomized Clinical Trial, HEREDITARY HEMOCHROMATOSIS, IRON",

author = "Annick Vanclooster and {van Deursen}, Cees and Reggy Jaspers and David Cassiman and Ger Koek",

year = "2017",

month = sep,

doi = "10.1053/j.gastro.2017.06.006",

language = "English",

volume = "153",

pages = "678--680.e2",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "Elsevier Saunders",

number = "3",

}

TY - JOUR

T1 - Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis

T2 - Double-Blind Randomized Placebo-Controlled Trial

AU - Vanclooster, Annick

AU - van Deursen, Cees

AU - Jaspers, Reggy

AU - Cassiman, David

AU - Koek, Ger

PY - 2017/9

Y1 - 2017/9

N2 - Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performedwhen serum ferritin was >100 mu g/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy.

AB - Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performedwhen serum ferritin was >100 mu g/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy.

KW - Hereditary Hemochromatosis

KW - Proton Pump Inhibitors

KW - Randomized Clinical Trial

KW - HEREDITARY HEMOCHROMATOSIS

KW - IRON

U2 - 10.1053/j.gastro.2017.06.006

DO - 10.1053/j.gastro.2017.06.006

M3 - Article

C2 - 28624580

SN - 0016-5085

VL - 153

SP - 678-680.e2

JO - Gastroenterology

JF - Gastroenterology

IS - 3

ER -